IQVIA Holdings Inc. (IQV)
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will IQVIA (IQV) Beat Estimates Again in Its Next Earnings Report?
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IQVIA Benefits From Global IT Infrastructure Amid Low Liquidity
The IQV stock gains from its $330-billion addressable market and an enormous trove of data, which is its distinguishing asset.
IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Iqvia initiated with an Overweight at Stephens
Stephens initiated coverage of Iqvia with an Overweight rating and $250 price target. The firm says the company has "fulfilled the promise" of combining a leading contract research organization and the largest life science data repository to connect intelligence that advances healthcare. The analyst views the company's Q3 reset, as well as the recent outline of "reasonably conservative" fiscal 2025 and long-term growth frameworks, as creating an attractive setup "for a well-run industry bellwether."
IQVIA Holdings: Share Price Disconnected From Growth Outlook
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term revenue estimates of $28.45B by 2033 support a bullish outlook.
Why You Should Retain IQVIA Holdings Stock in Your Portfolio Now
IQV is known for its innovative use of technology and data analytics.
Interpreting IQVIA (IQV) International Revenue Trends
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
